Along this line, it is noteworthy that a reversible p97 inhibitor named CB-5083 has produced promising anti-cancer effects in mouse xenograft tumor models and is now being evaluated in clinical trials (Anderson et al., 2015; Zhou et al., 2015). The gene discussed is VCP; the disease is cancer.